Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.
Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.
复制标题
DOI：
10.3390/cancers5010064
复制
发表时间：
2013-01-21
期刊：
影响因子：
5.2
通讯作者：
Geldart T
中科院分区：
文献类型：
--
作者：
Cidon EU;Ellis SG;Inam Y;Adeleke S;Zarif S;Geldart T
胃癌（GC）是全球主要的癌症负担，并且仍然是癌症相关死亡的第二大原因。由于其隐匿性，发病通常较晚，且预后往往较差。尽管在过去十年中治疗方式有所改进，但对于大多数患者来说，总体生存率仅略有改善。最近在了解 GC 分子生物学及其信号通路方面取得的进展，为选定的患者群体带来了临床上重大进展的希望。 Her-2 过度表达或扩增的患者已从单克隆抗体（例如曲妥珠单抗）与标准化疗的整合中受益。此外，针对血管生成的药物（贝伐珠单抗、索拉非尼、舒尼替尼）正在研究中，其他靶向药物如 mTOR 抑制剂、抗 c-MET、polo 样激酶 1 抑制剂也处于临床前或早期临床开发阶段。现在的关键是患者的选择和可靠的生物标志物的开发，以准确地选择最有可能从这些定制疗法中受益的患者。未来的试验应重点关注这些进展，以优化 GC 患者的治疗。本文将回顾GC靶向药物的最新进展和现状。
Gastric cancer (GC) represents a major cancer burden worldwide, and remains the second leading cause of cancer-related death. Due to its insidious nature, presentation is usually late and often carries a poor prognosis. Despite having improved treatment modalities over the last decade, for most patients only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and its signaling pathways, offers the hope of clinically significant promising advances for selected groups of patients. Patients with Her-2 overexpression or amplification have experienced benefit from the integration of monoclonal antibodies such as trastuzumab to the standard chemotherapy. Additionally, drugs targeting angiogenesis (bevacizumab, sorafenib, sunitinib) are under investigation and other targeted agents such as mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors are in preclinical or early clinical development. Patient selection and the development of reliable biomarkers to accurately select patients most likely to benefit from these tailored therapies is now key. Future trials should focus on these advances to optimize the treatment for GC patients. This article will review recent progress and current status of targeted agents in GC.